Abstract

PurposeAccording to a few recent studies, the clinical phenotype of Graves’ disease (GD) at onset is becoming milder in recent years, in terms of prevalence and severity of hyperthyroidism, goiter and overt eye disease. The aim of this study was to assess the change in GD phenotype across the late twentieth and the early twenty-first centuries.Materials and methodsWe carried out a systematic search of studies published between 1/1/1980 and 12/31/2017 describing naïve GD patients at diagnosis. We collected epidemiological, clinical, biochemical and serological data reported in the selected studies, and (1) conducted a single-arm meta-analysis to compare clinical and biochemical characteristics of naïve GD patients before and after year 2000 and (2) performed a meta-regression to identify the trend of the observed clinical presentations.ResultsEighty selected articles were related to the period before the year 2000, 30 to the years 2000–2017. According to demographics, the two defined populations were homogeneous at meta-analysis: overall estimated female prevalence was 81% [95% CI 79–82], mean estimated age of the entire population was 39.8 years [95% CI 38.4–41.1], with no significant differences between pre- and post-2000 groups (p > 0.05). The overall estimated prevalence of smokers was 40% [95% CI 33–46], with no significant difference between the two groups (p > 0.05). Mean estimated free thyroxine (FT4) and free triiodothyronine (FT3) levels at diagnosis were higher in the pre-2000 group: 4.7 ng/dl [95% CI 4.5–4.9] for FT4 and 14.2 pg/ml [95% CI 13.3–15.1] for FT3, as compared to the post-2000 group: 3.9 ng/dl [95% CI 3.6–4.2] for FT4 and 12.1 pg/ml [95% CI 11.0–13.3] for FT3 (all p < 0.01). Goiter estimated prevalence was higher in the pre-2000 group, 87% [95% CI 84–90], than in the post-2000 group, 56% [95% CI 45–67]. Estimated prevalence for Graves’ Orbitopathy (GO) was 34% [95% CI 27–41] in the pre-2000 group and 25% [95% CI 19–30] in the post-2000 group (p = 0.03). Accordingly, meta-regression adjusted for covariates showed an average annual reduction of FT4 (− 0.040 ± 0.008 ng/dl, p < 0.0001), FT3 (− 0.316 ± 0.019 pg/ml, p < 0.0001), goiter prevalence (− 0.023 ± 0.008%, p = 0.006), and goiter size (− 0.560 ± 0.031 ml, p < 0.0001).ConclusionsOur meta-analysis and meta-regression confirmed that GD phenotype at diagnosis is nowadays milder than in the past; we hypothesize that conceivable factors involved in this change are iodoprophylaxis, worldwide decrease in smoking habits, larger use of contraceptive pill and micronutrient supplementation, as well as earlier diagnosis and management.

Highlights

  • Graves’ disease (GD) is the most common cause of hyperthyroidism in iodine-sufficient areas [1], caused by antibodies directed against the TSH-receptor (TRAb)

  • GD occurs at any age, with the highest risk of onset in the 3rd–5th decades of life, and a

  • TRAb are responsible for the main clinical manifestations of the disease: hyperthyroidism, goiter and orbitopathy, the so-called “Merseburg triad”, by the name of the German city in which the physician Karl von Basedow practiced and described the clinical pattern of this disease [6]

Read more

Summary

Introduction

Graves’ disease (GD) is the most common cause of hyperthyroidism in iodine-sufficient areas [1], caused by antibodies directed against the TSH-receptor (TRAb). Cumulative lifetime risk to develop GD is 3% for women and 0.5% for men [2], with an incidence of 20–50 cases/100,000 people per year [3]. TRAb are responsible for the main clinical manifestations of the disease: hyperthyroidism, goiter and orbitopathy, the so-called “Merseburg triad”, by the name of the German city in which the physician Karl von Basedow practiced and described the clinical pattern of this disease [6]. Graves’ orbitopathy (GO) incidence is reported to be 16 cases per 100,000 per year in females and 3 cases per 100,000 in males [7]. Besides GO, rare extrathyroidal manifestations include thyroid dermopathy (or pretibial myxedema) and acropachy [8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call